HHS Finds that FDA Does Not Have the Authority to Regulate Laboratory Developed Tests

FDA maze of regulations
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on pinterest
Pinterest
Share on whatsapp
WhatsApp
Share on email
Email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

LDTs now fall under relaxed FDA regulations with rescission of HHS guidances.

The US Department of Health and Human Services (HHS) published a notice Aug. 19, 2020, addressing the regulation of laboratory-developed tests (LDTs). This new guidance indicates that the US Food and Drug Administration (FDA) does not have the authority to regulate LDTs, and the LDTs will not require any FDA premarket review.

The notice by the HHS states, “The department has determined that the FDA will not require premarket review of LDT absent notice-and-comment rulemaking, as opposed to through guidance documents, compliance manuals, website statements, or other informal issuances.”

While not required, HHS further said, “Those seeking approval or clearance of, or an emergency use authorization (“EUA”) for an LDT may nonetheless voluntarily submit a premarket approval application, premarket notification or an EUA request, respectively, but are not required to do so, and FDA will adjudicate those submissions.”

HHS also provided criteria that those using LDTs must still consider: “Those opting to use LDTs in their laboratories without FDA premarket review or authorization may do so with the understanding that they would not be eligible for PREP Act coverage absent approval, clearance or authorization and would remain subject to regulation by the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendments of 1988, and its implementing regulations.”

Clinical laboratory leaders who wish to review the full text of the HHS notice can view it here.

Related Resources:

Rescission of Guidances and Other Informal Issuances Concerning Premarket Review of Laboratory Developed Tests

COVID-19 TESTING DATA

Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at rmichel@darkreport.com.

Sincerely,

Robert L. Michel
President, Founder
The Dark Intelligence Group